| Anemia |
NCT04626414: Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers |
|
|
| Recruiting | 1 | 32 | US | Ferric maltol capsule, ST10, Feraccru, Accrufer, Ferric maltol suspension, ST10 | Shield Therapeutics | Anemia, Iron Deficiency | 11/20 | 11/20 | | |
NCT03814408: A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A |
|
|
| Active, not recruiting | 1 | 2 | US | RP-L102 | Rocket Pharmaceuticals Inc. | Fanconi Anemia Complementation Group A | 12/20 | 03/22 | | |
NCT04775615: Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects. |
|
|
| Not yet recruiting | 1 | 36 | NA | DDO-3055 tablets；Placebo | Jiangsu HengRui Medicine Co., Ltd. | Renal Anemia | 05/21 | 06/21 | | |
NCT04470063: Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases. |
|
|
| Enrolling by invitation | 1 | 30 | RoW | DDO-3055 tablets, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Anemia Associated Chronic Kidney Disease | 12/21 | 12/21 | | |
NCT05088655: A Bioequivalence Study of Hetrombopag in Healthy Subjects |
|
|
| Completed | 1 | 58 | RoW | Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | Sever Aplastic Anaemia | 07/22 | 11/23 | | |
| Not yet recruiting | 1 | 60 | RoW | HEC53856 | Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd. | Hemodialysis, Peritoneal Dialysis | 09/22 | 01/23 | | |
NCT04439006: Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization |
|
|
| Completed | 1 | 10 | US | Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765 | Jennifer Woyach, Janssen Scientific Affairs, LLC | Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed | 09/22 | 09/22 | | |
CKD, NCT05636891: Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in Patients on Dialysis |
|
|
| Active, not recruiting | 1 | 43 | RoW | Stimus | Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, Clinical Research Consultants, Inc., Clinical Research Viet Nam Skill Training And Consultant Company Limited | Chronic Kidney Disease | 11/22 | 12/22 | | |
| Not yet recruiting | 1 | 60 | RoW | HEC53856, Roxadustat, Placebo | Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd. | Chronic Kidney Diseases, Renal Anemia | 12/22 | 05/23 | | |
| Recruiting | 1 | 76 | RoW | SSS17, Placebo | Shenyang Sunshine Pharmaceutical Co., LTD., The Fifth Affiliated Hospital of Guangzhou Medical University | Anemia in Chronic Kidney Diseases | 12/22 | 06/23 | | |
NCT03926819: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers |
|
|
| Completed | 1 | 20 | US | HBI-002 | Hillhurst Biopharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Anemia, Sickle Cell | 04/23 | 04/23 | | |
NCT04255875: Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease |
|
|
| Completed | 1 | 52 | US | Placebo, PF-07209326 | Pfizer | Healthy, Sickle Cell Anemia | 07/23 | 07/23 | | |
NCT06080555: Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia |
|
|
| Completed | 1 | 84 | RoW | Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Ferinject] | Sichuan Huiyu Pharmaceutical Co., Ltd, The First Hospital of Jilin University, Suzhou Guochen Biotek Co., Ltd., Boji Data Technology (Beijing) Co., Ltd., Boji Medical Technology Co., Ltd. | Iron Deficiency, Anaemia | 01/24 | 03/24 | | |
NCT05745883: Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia |
|
|
| Recruiting | 1 | 32 | US | DISC-0974, Placebo | Disc Medicine, Inc | Chronic Kidney Diseases, Anemia of Chronic Kidney Disease | 09/24 | 05/25 | | |
NCT06231368: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. |
|
|
| Recruiting | 1 | 6 | RoW | CNCT19 CAR-T cell therapy | Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd. | Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy | 01/25 | 08/25 | | |
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease |
|
|
| Completed | 1 | 122 | Europe, US | AG-946, AG-946 Matched Placebo | Agios Pharmaceuticals, Inc. | Healthy Volunteers, Anemia, Sickle Cell | 12/23 | 12/23 | | |
NCT04478227: TPO-Mimetic Use in Children for Hematopoietic Failure |
|
|
| Active, not recruiting | 1 | 15 | US | Romiplostim, Nplate | Anjali Sharathkumar, Amgen | Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS) | 01/24 | 06/24 | | |
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies |
|
|
| Not yet recruiting | 1 | 8 | NA | Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC | Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis | 06/26 | 12/26 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT05660265: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years |
|
|
| Recruiting | 1 | 40 | US | GSK4172239D, Placebo | GlaxoSmithKline | Hematologic Diseases, Anaemia, Sickle Cell | 03/25 | 03/25 | | |
NCT05169580: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 |
|
|
| Recruiting | 1 | 70 | US | FTX-6058 oral capsule(s) | Fulcrum Therapeutics | Sickle Cell Disease, Sickle Cell Anemia | 04/25 | 04/25 | | |
NCT05773586: A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients |
|
|
| Recruiting | 1 | 105 | RoW | APG-5918, Placebo | Ascentage Pharma Group Inc. | Anemia | 08/25 | 03/26 | | |
NCT04802057: Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088 |
|
|
| Active, not recruiting | 1 | 9 | Europe | SAR445088 | Bioverativ, a Sanofi company | Autoimmune Haemolytic Anaemia | 01/26 | 01/26 | | |
